Katherine L Nathanson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5621231/publications.pdf

Version: 2024-02-01

347 papers	34,049 citations	3525 90 h-index	4545 171 g-index
363 all docs	363 docs citations	363 times ranked	42371 citing authors

#	Article	IF	Citations
1	Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. Leukemia, 2022, 36, 283-287.	3.3	17
2	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
3	Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon. Gastrointestinal Endoscopy Clinics of North America, 2022, 32, 95-112.	0.6	1
4	Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank. Genetics in Medicine, 2022, 24, 601-609.	1.1	13
5	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. Genetics in Medicine, 2022, 24, 564-575.	1.1	8
6	Uncommon variants in FLG2 and TCHHL1 are associated with remission of atopic dermatitis in a large longitudinal US cohort. Archives of Dermatological Research, 2022, 314, 953-959.	1.1	6
7	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
8	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Research, 2022, 82, OT2-18-01-OT2-18-01.	0.4	1
9	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants. JAMA Oncology, 2022, 8, 587.	3.4	36
10	Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes. Cancer Research, 2022, 82, P2-09-01-P2-09-01.	0.4	0
11	PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. JCO Precision Oncology, 2022, 6, e2100159.	1.5	4
12	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. Human Molecular Genetics, 2022, 31, 3133-3143.	1.4	11
13	Epigenetic age acceleration in U.S. testicular cancer survivors (TCS).. Journal of Clinical Oncology, 2022, 40, 5033-5033.	0.8	1
14	Trends in and determinants of germline BRCA1/2 testing in patients with breast and ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 10583-10583.	0.8	0
15	Association Study between Polymorphisms in DNA Methylationâ€“Related Genes and Testicular Germ Cell Tumor Risk. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1769-1779.	1.1	4
16	A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.. Journal of Clinical Oncology, 2022, 40, 4131-4131.	0.8	2
17	TSLP and IL-7R Variants Are Associated with Persistent Atopic Dermatitis. Journal of Investigative Dermatology, 2021, 141, 446-450.e2.	0.3	16
18	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. Genetics in Medicine, 2021, 23, 603-605.	1.1	29

#	Article	IF	Citations
19	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
20	From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. JCO Precision Oncology, 2021, 5, 403-407.	1.5	3
21	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	13.9	414
22	Clinical Management of Oligopolyposis of Unknown Etiology. Current Treatment Options in Gastroenterology, 2021, 19, 183-197.	0.3	5
23	Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1275-1278.	1.1	2
24	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. Journal of the National Cancer Institute, 2021, 113, 1168-1176.	3.0	41
25	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. American Journal of Human Genetics, 2021, 108, 564-582.	2.6	18
26	HLA Class I Polymorphisms Influencing Both Peptide Binding and KIR Interactions Are Associated with Remission among Children with Atopic Dermatitis: A Longitudinal Study. Journal of Immunology, 2021, 206, 2038-2044.	0.4	8
27	Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. JCO Precision Oncology, 2021, 5, 988-1000.	1.5	10
28	Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine, 2021, 27, 985-992.	15.2	67
29	Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression. Molecular Cancer Research, 2021, 19, 1476-1485.	1.5	11
30	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. Journal of General Internal Medicine, 2021, , 1.	1.3	2
31	Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4028-e4038.	1.8	13
32	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
33	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nature Communications, 2021, 12, 4198.	5.8	24
34	Identification of 22 susceptibility loci associated with testicular germ cell tumors. Nature Communications, 2021, 12, 4487.	5.8	27
35	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Journal of Clinical Oncology, 2021, 39, 3430-3440.	0.8	21
36	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. JAMA Oncology, 2021, 7, 1045.	3.4	21

#	Article	IF	Citations
37	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966.	2.0	11
38	EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 1033-1040.	0.7	5
39	Using a Machine Learning Approach to Identify Low-Frequency and Rare FLG Alleles Associated with Remission of Atopic Dermatitis. JID Innovations, 2021, 1, 100046.	1.2	3
40	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. Journal of Clinical Oncology, 2021, 39, 2564-2573.	0.8	47
41	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. Journal of Clinical Oncology, 2021, 39, 2497-2505.	0.8	113
42	CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports Medicine, 2021, 2, 100394.	3.3	29
43	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	0.8	22
44	Uptake and outcomes of small intestinal and urinary tract cancer surveillance in Lynch syndrome. World Journal of Clinical Oncology, 2021, 12, 1023-1036.	0.9	1
45	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
46	Filaggrin sequencing and bioinformatics tools. Archives of Dermatological Research, 2020, 312, 155-158.	1.1	13
47	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
48	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
49	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. British Journal of Cancer, 2020, 122, 333-339.	2.9	141
50	Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations. Clinical Gastroenterology and Hepatology, 2020, 18, 505-508.e1.	2.4	16
51	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
52	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.4	32
53	Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. Cancer Genetics, 2020, 248-249, 49-56.	0.2	0
54	Tumor detection rates in screening of individuals with SDHx-related hereditary paragangliomaâ€“pheochromocytoma syndrome. Genetics in Medicine, 2020, 22, 2101-2107.	1.1	20

#	Article	IF	Citations
55	Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4661-e4670.	1.8	40
56	Upper Endoscopic Surveillance in Lynch Syndrome Detects Gastric and Duodenal Adenocarcinomas. Cancer Prevention Research, 2020, 13, 1047-1054.	0.7	23
57	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	2.3	5
58	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	1.5	9
59	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. American Journal of Gastroenterology, 2020, 115, 2095-2097.	0.2	9
60	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. Journal of Investigative Dermatology, 2020, 140, 2242-2252.e7.	0.3	23
61	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
62	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2020, 112, 1213-1221.	3.0	51
63	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2020, 22, 1142-1148.	1.1	59
64	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. Genetics in Medicine, 2020, 22, 1401-1406.	1.1	4
65	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
66	Associations of sociodemographic and clinical factors with gastrointestinal cancer risk assessment appointment completion. Journal of Genetic Counseling, 2020, 29, 616-624.	0.9	3
67	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	5.8	75
68	Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. Clinical Genetics, 2020, 97, 601-609.	1.0	7
69	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32
70	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. Breast Cancer Research and Treatment, 2020, 181, 181-188.	1.1	36
71	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	1.3	16
72	Lower abdominal and pelvic radiation and testicular germ cell tumor risk. PLoS ONE, 2020, 15, e0239321.	1.1	8

#	Article	IF	Citations
73	Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms. Blood, 2020, 136, 2-4.	0.6	1
74	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell, 2019, 178, 933-948.e14.	13.5	301
75	Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis. JAMA Dermatology, 2019, 155, 1269.	2.0	39
76	Role of endoscopy in the management of hereditary diffuse gastric cancer syndrome. World Journal of Gastroenterology, 2019, 25, 2878-2886.	1.4	29
77	In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Molecular Cancer Therapeutics, 2019, 18, 1637-1648.	1.9	14
78	Research participantsâ€™ experiences with return of genetic research results and preferences for webâ€based alternatives. Molecular Genetics & Genomic Medicine, 2019, 7, e898.	0.6	24
79	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
80	Association between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistence. Annals of Allergy, Asthma and Immunology, 2019, 123, 595-601.e1.	0.5	13
81	Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening. BioTechniques, 2019, 67, 118-122.	0.8	11
82	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
83	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncology, 2019, 5, 514.	3.4	43
84	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
85	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19
86	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
87	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
88	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. Clinical Cancer Research, 2019, 25, 4363-4374.	3.2	60
89	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	15.2	466
90	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. JCO Precision Oncology, 2019, 3, 1-11.	1.5	20

#	Article	IF	Citations
91	Preferences for inâ€person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. Clinical Genetics, 2019, 95, 293-301.	1.0	16
92	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. Gastroenterology, 2019, 156, 273-274.	0.6	19
93	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology, 2019, 46, 190-194.	0.7	6
94	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
95	Response to Hannah-Shmouni and Stratakis. Genetics in Medicine, 2019, 21, 1256.	1.1	0
96	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. Journal of the National Cancer Institute, 2018, 110, 985-993.	3.0	35
97	Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent. Cancer Genetics, 2018, 224-225, 12-20.	0.2	7
98	Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibility. Human Reproduction, 2018, 33, 967-977.	0.4	10
99	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
100	Uncommon Filaggrin Variants Are Associated with Persistent Atopic Dermatitis in African Americans. Journal of Investigative Dermatology, 2018, 138, 1501-1506.	0.3	59
101	Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer. Cancer Immunology Research, 2018, 6, 276-287.	1.6	69
102	Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 116-118.	1.1	5
103	Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Research and Treatment, 2018, 168, 703-712.	1.1	42
104	Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2018, 20, 671-682.	1.1	128
105	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	3.2	29
106	Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. International Journal of Cancer, 2018, 142, 36-43.	2.3	11
107	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. JCO Precision Oncology, 2018, 2, 1-9.	1.5	30
108	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. JCO Precision Oncology, 2018, 2, 1-24.	1.5	15

#	Article	IF	Citations
109	Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. JCO Precision Oncology, 2018, 2, 1-12.	1.5	10
110	CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing. Genome Biology, 2018, 19, 202.	3.8	62
111	A practical approach to adjusting for population stratification in genome-wide association studies: principal components and propensity scores (PCAPS). Statistical Applications in Genetics and Molecular Biology, 2018, 17, .	0.2	24
112	Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity. Cell Metabolism, 2018, 27, 1263-1280.e6.	7.2	85
113	Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. Molecular Carcinogenesis, 2018, 57, 1311-1318.	1.3	6
114	Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Reports, 2018, 23, 3392-3406.	2.9	324
115	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	7.7	532
116	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. European Journal of Human Genetics, 2017, 25, 432-438.	1.4	26
117	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280
118	Application of Panel-Based Tests for Inherited Risk of Cancer. Annual Review of Genomics and Human Genetics, 2017, 18, 201-227.	2.5	26
119	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. Nature Communications, 2017, 8, 15034.	5.8	40
120	Von Hippelâ€“Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clinical Cancer Research, 2017, 23, e68-e75.	3.2	205
121	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. Clinical Cancer Research, 2017, 23, e83-e90.	3.2	122
122	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	2.3	108
123	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature, 2017, 546, 431-435.	13.7	938
124	A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2017, 175, 304-314.	0.7	50
125	Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nature Genetics, 2017, 49, 1141-1147.	9.4	105
126	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356

#	Article	IF	Citations
127	Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1016-1026.	1.1	24
128	Pheochromocytoma and Paraganglioma Susceptibility Genes. JAMA Oncology, 2017, 3, 1212.	3.4	4
129	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
130	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications, 2017, 8, 319.	5.8	212
131	Allele-specific copy number estimation by whole exome sequencing. Annals of Applied Statistics, 2017, 11, 1169-1192.	0.5	8
132	Association of breast cancer risk and the mTOR pathway in women of African ancestry in â€˜The Rootâ€™ Consortium. Carcinogenesis, 2017, 38, 789-796.	1.3	6
133	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	2.9	72
134	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
135	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clinical Cancer Research, 2017, 23, e107-e114.	3.2	91
136	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clinical Cancer Research, 2017, 23, e123-e132.	3.2	55
137	A functionally significant SNP in TP53 and breast cancer risk in African-American women. Npj Breast Cancer, 2017, 3, 5.	2.3	44
138	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
139	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263.	0.8	1
140	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
141	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight, 2017, 2, e89760.	2.3	55
142	Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. PLoS Genetics, 2017, 13, e1006719.	1.5	98
143	Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway.. Journal of Clinical Oncology, 2017, 35, e13015-e13015.	0.8	0
144	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	1.1	10

#	Article	IF	Citations
145	Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS ONE, 2016, 11, e0157125.	1.1	8
146	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology, 2016, 2, 1434.	3.4	189
147	Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. Human Genetics, 2016, 135, 1145-1159.	1.8	32
148	Enhancing the evaluation of <scp>PI</scp>3K inhibitors through 3DÂmelanoma models. Pigment Cell and Melanoma Research, 2016, 29, 317-328.	1.5	12
149	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
150	Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. Clinical Genitourinary Cancer, 2016, 14, 524-529.	0.9	1
151	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American Journal of Human Genetics, 2016, 98, 801-817.	2.6	113
152	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
153	Population Frequency of Germline BRCA1/2 Mutations. Journal of Clinical Oncology, 2016, 34, 4183-4185.	0.8	107
154	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Human Molecular Genetics, 2016, 25, ddw305.	1.4	50
155	Genetic changes associated with testicular cancer susceptibility. Seminars in Oncology, 2016, 43, 575-581.	0.8	26
156	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078.	0.8	147
157	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	7.7	41
158	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	2.2	42
159	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	5.8	93
160	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
161	Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature Reviews Clinical Oncology, 2016, 13, 581-588.	12.5	258
162	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. Genetics in Medicine, 2016, 18, 25-33.	1.1	56

#	Article	IF	Citations
163	Genomic Biomarkers for Breast Cancer Risk. Advances in Experimental Medicine and Biology, 2016, 882, 1-32.	0.8	42
164	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
165	Personalized Preclinical Trials in BRAF Inhibitorâ€"Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	3.2	108
166	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	3.0	77
167	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clinical Cancer Research, 2016, 22, 374-382.	3.2	38
168	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
169	Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. JCI Insight, 2016, 1, e88207.	2.3	38
170	PIM kinases as therapeutic targets against advanced melanoma. Oncotarget, 2016, 7, 54897-54912.	0.8	16
171	Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget, 2016, 7, 71211-71222.	0.8	20
172	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget, 2016, 7, 48577-48585.	0.8	6
173	Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.. Journal of Clinical Oncology, 2016, 34, 1515-1515.	0.8	2
174	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
175	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clinical Epigenetics, 2015, 7, 58.	1.8	19
176	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	1.1	34
177	Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. New England Journal of Medicine, 2015, 372, 2243-2257.	13.9	764
178	Rare inactivating PDE11A variants associated with testicular germ cell tumors. Endocrine-Related Cancer, 2015, 22, 909-917.	1.6	24
179	DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. Journal of Translational Medicine, 2015, 13, 335.	1.8	16
180	Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6140.	5.8	143

#	Article	IF	Citations
181	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
182	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	3.8	390
183	Association of HLA-DRB1 genetic variants with the persistence of atopic dermatitis. Human Immunology, 2015, 76, 571-577.	1.2	15
184	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	3.2	17
185	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genetics in Medicine, 2015, 17, 630-638.	1.1	128
186	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 2015, 17, 485-492.	1.1	79
187	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
188	Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.. Journal of Clinical Oncology, 2015, 33, 1511-1511.	0.8	1
189	Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer.. Journal of Clinical Oncology, 2015, 33, 1562-1562.	0.8	1
190	Molecular Diagnostics and Tumor Mutational Analysis. Cancer Drug Discovery and Development, 2015, , 47-65.	0.2	2
191	Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer.. Journal of Clinical Oncology, 2015, 33, e12503-e12503.	0.8	0
192	Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer.. Journal of Clinical Oncology, 2015, 33, 541-541.	0.8	3
193	Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. Cancer Immunology Research, 2014, 2, 1051-1058.	1.6	74
194	Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2Î± Activity. Cancer Discovery, 2014, 4, 53-60.	7.7	79
195	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	2.2	97
196	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy, 2014, 10, 1369-1379.	4.3	309
197	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
198	Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention. Science, 2014, 343, 1466-1470.	6.0	300

#	Article	IF	Citations
199	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clinical Cancer Research, 2014, 20, 5537-5546.	3.2	169
200	Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer. Genetics in Medicine, 2014, 16, 827-829.	1.1	12
201	A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer. Cancer Cell, 2014, 26, 344-357.	7.7	361
202	Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. Human Molecular Genetics, 2014, 23, 6061-6068.	1.4	28
203	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. Clinical Cancer Research, 2014, 20, 3328-3337.	3.2	33
204	Hereditary Kidney Cancer Syndromes. Advances in Chronic Kidney Disease, 2014, 21, 81-90.	0.6	122
205	Prevalence of mutations in a panel of breast cancer susceptibility genes in patients with early onset breast cancer.. Journal of Clinical Oncology, 2014, 32, 1510-1510.	0.8	2
206	HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a.. Journal of Clinical Oncology, 2014, 32, e15611-e15611.	0.8	1
207	Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2014, 32, 412-412.	0.8	2
208	A look back: Results from 1 year of routine clinical testing of both hematologic and solid tumors using two targeted next-generation sequencing (NGS) panels.. Journal of Clinical Oncology, 2014, 32, e22099-e22099.	0.8	0
209	microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.. Journal of Clinical Oncology, 2014, 32, 9048-9048.	0.8	0
210	Germ-line DICER1 mutations do not make a major contribution to the etiology of familial testicular germ cell tumours. BMC Research Notes, 2013, 6, 127.	0.6	13
211	Cutaneous Hamartoneoplastic Disorders. , 2013, , 1-13.		0
212	Immunotherapy at Large: The road to personalized cancer vaccines. Nature Medicine, 2013, 19, 1098-1100.	15.2	50
213	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	9.4	270
214	Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Human Molecular Genetics, 2013, 22, 2748-2753.	1.4	59
215	A Classification Model for BRCA2 DNA Binding Domain Missense Variants Based on Homology-Directed Repair Activity. Cancer Research, 2013, 73, 265-275.	0.4	103
216	The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research, 2013, 19, 1784-1794.	3.2	98

#	Article	IF	Citations
217	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
218	The Molecular Biology of Renal Cell Carcinoma. Seminars in Oncology, 2013, 40, 421-428.	0.8	40
219	Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Research, 2013, 15, 212.	2.2	52
220	A genome-wide association study of breast cancer in women of African ancestry. Human Genetics, 2013, 132, 39-48.	1.8	70
221	Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Reports, 2013, 4, 1090-1099.	2.9	162
222	Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing. Annals of Surgical Oncology, 2013, 20, 1444-1450.	0.7	182
223	Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nature Genetics, 2013, 45, 680-685.	9.4	154
224	A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nature Genetics, 2013, 45, 690-696.	9.4	232
225	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis, 2013, 34, 1520-1528.	1.3	26
226	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	1.5	105
227	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
228	Comparison of Address-based Sampling and Random-digit Dialing Methods for Recruiting Young Men as Controls in a Case-Control Study of Testicular Cancer Susceptibility. American Journal of Epidemiology, 2013, 178, 1638-1647.	1.6	27
229	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research, 2013, 19, 4868-4878.	3.2	167
230	Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer. Cancer Discovery, 2013, 3, 399-405.	7.7	124
231	Risk of metachronous breast cancer after BRCA mutationâ€“associated ovarian cancer. Cancer, 2013, 119, 1344-1348.	2.0	58
232	Retrospective, correlative study of BRAF mutation V600E in testicular cancer patients.. Journal of Clinical Oncology, 2013, 31, e15584-e15584.	0.8	1
233	The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling. PLoS ONE, 2013, 8, e59588.	1.1	58
234	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLoS ONE, 2013, 8, e69748.	1.1	3

#	Article	IF	Citations
235	NRAS and BRAF mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib.. Journal of Clinical Oncology, 2013, 31, 9017-9017.	0.8	0
236	The mutational spectrum of breast and ovarian tumors from BRCA1 and BRCA2 mutation carriers.. Journal of Clinical Oncology, 2013, 31, 1510-1510.	0.8	0
237	Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). Frontiers in Endocrinology, 2012, 3, 163.	1.5	12
238	A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1362-1370.	1.1	23
239	Genetic Susceptibility to Type 2 Diabetes and Breast Cancer Risk in Women of European and African Ancestry. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 552-556.	1.1	10
240	Molecular Testing in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 117-123.	1.0	22
241	Hybrid peripheral nerve sheath tumor. Journal of Neurosurgery, 2012, 117, 897-901.	0.9	17
242	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
243	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 136, 295-302.	1.1	4
244	Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genetics, 2012, 205, 1-11.	0.2	177
245	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
246	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis, 2012, 33, 835-840.	1.3	64
247	Integrative Genomic Analyses of Sporadic Clear Cell Renal Cell Carcinoma Define Disease Subtypes and Potential New Therapeutic Targets. Cancer Research, 2012, 72, 112-121.	0.4	57
248	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2012, 132, 1119-1126.	1.1	8
249	ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Human Mutation, 2012, 33, 2-7.	1.1	269
250	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
251	Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Research and Treatment, 2012, 132, 341-345.	1.1	12
252	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Research, 2011, 71, 5792-5805.	0.4	49

#	Article	IF	Citations
253	Therapeutic Approaches for Women Predisposed to Breast Cancer. Annual Review of Medicine, 2011, 62, 295-306.	5.0	33
254	Exploring the link between MORF4L1 and risk of breast cancer. Breast Cancer Research, 2011, 13, R40.	2.2	23
255	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
256	PALB2 mutations in familial breast and pancreatic cancer. Familial Cancer, 2011, 10, 225-231.	0.9	102
257	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Human Genetics, 2011, 130, 685-699.	1.8	18
258	Identification of intragenic deletions and duplication in the FLCN gene in Birtâ€Hoggâ€ÐubÃ© syndrome. Genes Chromosomes and Cancer, 2011, 50, 466-477.	1.5	50
259	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	1.5	90
260	PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. Cancer Research, 2011, 71, 2750-2760.	0.4	488
261	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2011, 20, 3304-3321.	1.4	68
262	Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1690-1702.	1.1	17
263	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
264	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Human Molecular Genetics, 2011, 20, 4732-4747.	1.4	32
265	A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Human Molecular Genetics, 2011, 20, 3109-3117.	1.4	124
266	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute, 2011, 103, 105-116.	3.0	40
267	Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nature Medicine, 2011, 17, 941-943.	15.2	155
268	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	2.6	91
269	Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma. Clinical Cancer Research, 2011, 17, 3478-3489.	3.2	213
270	Distinct MHC gene expression patterns during progression of melanoma. Genes Chromosomes and Cancer, 2010, 49, 144-154.	1.5	31

#	Article	IF	Citations
271	Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanoma. Biochemical Pharmacology, 2010, 80, 755-761.	2.0	33
272	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18, 683-695.	7.7	1,139
273	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	13.7	1,610
274	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	9.4	309
275	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2010, 19, 2886-2897.	1.4	60
276	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	1.1	37
277	Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology, 2010, 74, 1716-1723.	1.5	134
278	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. PLoS Genetics, 2010, 6, e1001183.	1.5	85
279	Diagnosis of Adult Hereditary Pulmonary Disease and the Role of Genetic Testing. Chest, 2010, 137, 976-982.	0.4	5
280	Taking the Guesswork Out of Uveal Melanoma. New England Journal of Medicine, 2010, 363, 2256-2257.	13.9	8
281	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes and Cancer, 2010, 1, 152-163.	0.6	283
282	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, R102.	2.2	25
283	Predisposition alleles for testicular germ cell tumour. Current Opinion in Genetics and Development, 2010, 20, 225-230.	1.5	26
284	The International Testicular Cancer Linkage Consortium: A clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 492-499.	0.8	42
285	Molecular Genetics of Testicular Germ Cell Tumor. , 2010, , 181-199.		0
286	HIF2Î± inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14391-14396.	3.3	176
287	Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy: Figure 1.. Cancer Research, 2009, 69, 3241-3244.	0.4	78
288	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes. Cancer Research, 2009, 69, 5312-5320.	0.4	103

#	Article	IF	Citations
289	Modification of Ovarian Cancer Risk by BRCA1/2-Interacting Genes in a Multicenter Cohort of BRCA1/2 Mutation Carriers. Cancer Research, 2009, 69, 5801-5810.	0.4	31
290	Multimodal Assessment of Protein Functional Deficiency Supports Pathogenicity of BRCA1 p.V1688del. Cancer Research, 2009, 69, 7030-7037.	0.4	16
291	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clinical Cancer Research, 2009, 15, 7711-7718.	3.2	104
292	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics, 2009, 18, 4442-4456.	1.4	99
293	Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. Clinical Cancer Research, 2009, 15, 1076-1085.	3.2	38
294	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. Pediatric Nephrology, 2009, 24, 1239-1242.	0.9	17
295	Deletion of 15q11.2â€“15q13.1 in isolated human hemimegalencephaly. Acta Neuropathologica, 2009, 118, 821-823.	3.9	4
296	No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2009, 115, 307-313.	1.1	9
297	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Research and Treatment, 2009, 117, 371-379.	1.1	12
298	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Familial Cancer, 2009, 8, 451-456.	0.9	21
299	Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nature Genetics, 2009, 41, 811-815.	9.4	319
300	Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Research, 2009, 11, R86.	2.2	75
301	Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Research, 2009, 11, R76.	2.2	44
302	Other Hereditary Breast Cancer Syndromes and Genes. , 2009, , 131-162.		0
303	Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes Chromosomes and Cancer, 2008, 47, 247-252.	1.5	37
304	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	2.6	257
305	HIF-Î± Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma. Cancer Cell, 2008, 14, 435-446.	7.7	441
306	The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families. Cancer Research, 2008, 68, 7006-7014.	0.4	100

#	Article	IF	Citations
307	The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel. Clinical Cancer Research, 2008, 14, 230-239.	3.2	214
308	Factors Determining Dissemination of Results and Uptake of Genetic Testing in Families with Known BRCA1/2 Mutations. Genetic Testing and Molecular Biomarkers, 2008, 12, 81-91.	1.7	130
309	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600Eâ€“mutated melanomas. Molecular Cancer Therapeutics, 2008, 7, 2876-2883.	1.9	284
310	Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression. Cancer Research, 2008, 68, 5743-5752.	0.4	90
311	Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization. Cancer Research, 2007, 67, 3594-3600.	0.4	65
312	AURKAF31I Polymorphism and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1416-1421.	1.1	30
313	Determination of Cancer Risk Associated with Germ Line BRCA1 Missense Variants by Functional Analysis. Cancer Research, 2007, 67, 1494-1501.	0.4	110
314	Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer. Clinical Cancer Research, 2007, 13, 7305-7313.	3.2	31
315	A Comparison of DNA Copy Number Profiling Platforms. Cancer Research, 2007, 67, 10173-10180.	0.4	62
316	RAD51 135Gâ†'C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	2.6	217
317	Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma. Journal of Molecular Diagnostics, 2007, 9, 464-471.	1.2	95
318	Network modeling links breast cancer susceptibility and centrosome dysfunction. Nature Genetics, 2007, 39, 1338-1349.	9.4	602
319	Large Genomic Rearrangement in BRCA1 and BRCA2 and Clinical Characteristics of Men with Breast Cancer in the United States. Clinical Breast Cancer, 2007, 7, 627-633.	1.1	7
320	The Tuberous Sclerosis Complex. New England Journal of Medicine, 2006, 355, 1345-1356.	13.9	1,570
321	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell & Melanoma Research, 2006, 19, 290-302.	4.0	483
322	A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes and Cancer, 2006, 45, 646-655.	1.5	111
323	The von Hippelâ€“Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma. American Journal of Medical Genetics, Part A, 2006, 140A, 685-690.	0.7	21
324	Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. Cancer Biology and Therapy, 2006, 5, 1098-1102.	1.5	28

#	Article	IF	Citations
325	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Human Molecular Genetics, 2006, 15, 443-451.	1.4	138
326	A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers: Table 1.. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2542-2545.	1.1	51
327	Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: Public health implications. Genetics in Medicine, 2005, 7, 28-33.	1.1	70
328	An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genetics in Medicine, 2005, 7, 34-39.	1.1	17
329	Inherited Susceptibility for Pediatric Cancer. Cancer Journal (Sudbury, Mass), 2005, 11, 255-267.	1.0	23
330	The Y Deletion gr/gr and Susceptibility to Testicular Germ Cell Tumor. American Journal of Human Genetics, 2005, 77, 1034-1043.	2.6	197
331	Somatic genetics of testicular cancer in relationship to prognosis. Cancer Biology and Therapy, 2004, 3, 1159-1161.	1.5	20
332	Resolving ATM Haplotypes in Whites. American Journal of Human Genetics, 2003, 72, 1071-1073.	2.6	1
333	Variants in CHEK2 Other than 1100delC Do Not Make a Major Contribution to Breast Cancer Susceptibility. American Journal of Human Genetics, 2003, 72, 1023-1028.	2.6	119
334	Pheochromocytoma: The Expanding Genetic Differential Diagnosis. Journal of the National Cancer Institute, 2003, 95, 1196-1204.	3.0	230
335	Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program. Journal of the National Cancer Institute, 2002, 94, 1365-1372.	3.0	611
336	Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 827-831.	3.3	73
337	CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. Human Molecular Genetics, 2002, 11, 1327-1332.	1.4	30
338	BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic. Journal of Clinical Oncology, 2002, 20, 994-999.	0.8	67
339	Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 2002, 31, 55-59.	9.4	1,001
340	Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. Oncogene, 2000, 19, 4170-4173.	2.6	35
341	Screening for Genomic Rearrangements in Families with Breast and Ovarian Cancer Identifies BRCA1 Mutations Previously Missed by Conformation-Sensitive Gel Electrophoresis or Sequencing. American Journal of Human Genetics, 2000, 67, 841-850.	2.6	149
342	Association of HPC2/ELAC2 Genotypes and Prostate Cancer. American Journal of Human Genetics, 2000, 67, 1014-1019.	2.6	133

#	Article	IF	Citations
343	Successful Use of Alternate Waste Nitrogen Agents and Hemodialysis in a Patient With Hyperammonemic Coma After Heart-Lung Transplantation. Archives of Neurology, 1999, 56, 481.	4.9	43
344	Multiple Vascular and Bowel Ruptures in an Adolescent Male with Sporadic Ehlers-Danlos Syndrome Type IV. Pediatric and Developmental Pathology, 1999, 2, 86-93.	0.5	26
345	I1307KAPC variant in non-Ashkenazi Jewish women affected with breast cancer. , 1999, 85, 189-190.		5
346	The APC I1307K allele and breast cancer risk. Nature Genetics, 1998, 20, 13-14.	9.4	65
347	Intestinal Perforation in Ehlers-Danlos Syndrome After Enema Treatment for Constipation. Journal of Pediatric Gastroenterology and Nutrition, 1998, 27, 599-602.	0.9	15